ORYZON is a clinical stage biopharmaceutical company that discovers and develops innovative personalized therapeutics for patients with cancers or neurodegenerative disorders. We are able to identify biomarkers through our platforms in genomics and proteomics and to translate them in advanced and personalized therapies.

Our Business model implies the identification of biomarkers that can be translated in new therapeutic targets and to invest in first in class programs mainly through the development of small molecules for two main indications: cancer and neurodegeneration. Oryzon typically develops its investigational medicines till proof of concept and then partners the program with pharmaceutical companies able to get the approval from the drug agencies to bring these medicines to the patients. In some special cases (orphan diseases), the company may keep its option to fully develop its programs.

We have a broad patent portfolio that protects our different programs.